B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund decreased its position in Pfizer, Inc. (NYSE:PFE) by 7.5% during the first quarter, Holdings Channel reports. The firm owned 130,468 shares of the biopharmaceutical company’s stock after selling 10,594 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Pfizer were worth $4,463,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in PFE. Asset Planning Services Ltd. raised its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the period. Orrstown Financial Services Inc. raised its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Cable Hill Partners LLC raised its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the period. D Orazio & Associates Inc. raised its position in shares of Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 28 shares during the period. Finally, Acropolis Investment Management LLC raised its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares during the period. Institutional investors own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (NYSE PFE) traded down 0.51% during trading on Friday, hitting $33.25. The stock had a trading volume of 12,928,473 shares. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.38. The company has a market cap of $198.43 billion, a PE ratio of 24.32 and a beta of 1.00. The firm’s 50 day moving average is $33.40 and its 200 day moving average is $33.31.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.64 earnings per share. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be paid a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. Pfizer’s dividend payout ratio is presently 94.12%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund-sells-10594-shares-of-pfizer-inc-pfe.html.

A number of brokerages have recently weighed in on PFE. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Barclays PLC reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $37.77.

In related news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.